| Name | Title | Contact Details |
|---|
On September 27, 2022, FedNat Insurance Company ("FNIC") was placed into receivership by the Florida Office of Insurance Regulation (OIR). The Florida Department of Financial Services (DFS) now has authority over FNICs operations; including bank accounts. A copy of the Liquidation Order for FedNat Insurance Company is available on the Departments website, www.myfloridacfo.com/division/receiver. The Department is currently gathering claim files and claim data to forward the information to applicable GAs. As a result, there may be a slight delay in claim processing during this transitional period. The Departments website, www.myfloridacfo.com/division/receiver, will be updated as appropriate regarding the claim transfer process. A Guaranty Association ("GA") is a nonprofit corporation statutorily created to provide a mechanism for the payment of policy related loss claims and unearned premium when an insurance company is liquidated. For more information, you can find specific information about your states Guaranty Association at: Alabama Insurance Guaranty Association - 205-823-4042 Florida Insurance Guaranty Association - https://figafacts.com/ Georgia Insurers Insolvency Pool – https://www.gaiga.org Louisiana Insurance Guaranty Association - https://www.laiga.org/ Mississippi Insurance Guaranty Association - https://ms-miga.com/ South Carolina Property and Casualty Insurance Guaranty Association - http://www.scguaranty.com/ Texas Property and Casualty Insurance Guaranty Association - http://www.tpciga.org/ For information on a bounced check or the time it will take to receive a replacement check contact the Department at 1-800-882-3054 or online at http://myfloridacf
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
MotoRad Ltd. is a global manufacturer of automotive components, specializing in thermal management systems. Established in 1958 and originally known as Fishman Engineering Ltd., the company is now owned by Fortissimo Investment Funds and employs 156 people. In 2025, MotoRad reported an annual revenue of $28.7 million, with Matt Buchholz serving as CEO. The company develops and manufactures a range of thermal management solutions, including thermostats, caps, and sensors. These products are designed for internal combustion engines, hybrid vehicles, plug-in hybrids, and battery electric vehicles. MotoRad serves automotive OEMs, aftermarket distributors, and industrial applications, ensuring a high level of product availability and a 97.81% global fill rate to meet customer needs. The company emphasizes innovation and collaborative work environments, focusing on employee development and technological advancement.